Accelerating Medicines Partnership® SCHIZOPHRENIA
The Accelerating Medicines Partnership (AMP®) Schizophrenia (SCZ) program aims to clarify the disease pathways and long-term outcomes of people who are at risk for schizophrenia and to identify new and better targets for early treatment.

Study Sites

Click on the pins below to learn more about the various Accelerating Medicines Partnership (AMP®) SCZ program study sites.

Last Reviewed on May 2, 2022